Radius Expands Non-US Market Footprint for TYMLOS injectable

 

• Globalization has been a key priority for the Company over the past two years
  

• Three additional market agreements now signed and executed:
  - Labatec Pharma SA: Switzerland, Middle East & North Africa (MENA) countries
  - Pharmbio Korea Inc.: South Korea
  - Biosidus: Colombia, South America

• Economics: upfront payments, regulatory & commercial milestones, and COGS margin

• Adds 13 new countries to the current non-US countries of Japan and Canada

• Japan: regulatory approval of 14-day cartridge anticipated in 2H 2022 followed by launch

• Canada: regulatory decision expected by the end of 2022

• EU and subsequently UK regulatory decisions expected in 2H 2022

https://finance.yahoo.com/news/radius-health-expands-non-us-120000852.html